P1-331: Familiality and linkage analysis of behavioral symptoms and age at disease onset in late-onset Alzheimer's disease

2006 ◽  
Vol 2 ◽  
pp. S194-S194 ◽  
Author(s):  
Paul Hollingworth ◽  
Marian Hamshere ◽  
Peter Holmans ◽  
Lesley Jones ◽  
Michael O'Donavan ◽  
...  
2006 ◽  
Vol 54 (9) ◽  
pp. 1348-1354 ◽  
Author(s):  
Paul Hollingworth ◽  
Marian L. Hamshere ◽  
Valentina Moskvina ◽  
Kimberley Dowzell ◽  
Pamela J. Moore ◽  
...  

1994 ◽  
Vol 7 (1) ◽  
pp. 39-45 ◽  
Author(s):  
Kazuhiko Kono ◽  
Fumio Kuzuya ◽  
Takayuki Yamamoto ◽  
Hidetoshi Endo

The clinical, psychological, and neurologic characteristics of 37 Japanese patients with early-onset Alzheimer's disease (eAD; onset before age 65 years) were compared with those of 23 patients with late-onset Alzheimer's disease (lAD; onset at age 65 years or later). This study evaluated brain atrophy using computed tomographic (CT) scans, and the behavioral and psychological differences in the two groups using the Gottfries-Bråne-Steen scale, Japanese revision (GBSS-JR). Follow-up CT scans were obtained and compared in 20 patients with eAD, 24 patients with lAD, and 23 elderly nondemented control subjects. The size of lateral cerebral ventricular dilation, measured every 6 months following admission, was significantly larger in the eAD patients than in the control subjects. The characteristics of the 37 patients with eAD were compared with those of the 23 patients with lAD by evaluating the scores on all 38 items in the five categories of the GBSS-JR. To compare the test results by duration of disease, patients were divided into subgroups according to average duration of disease: eAD1 (nine patients), 2.2 years; eAD2 (16 patients), 5.0 years; eAD3 (12 patients), 9.0 years; lAD1 (seven patients), 1.6 years; lAD2 (10 patients), 3.1 years; and lAD3 (six patients), 5.3 years. The GBSS-JR scores were compared in duration-matched pairs, that is, eAD1 versus lAD1 and eAD2 versus lAD3. The eAD1 patients showed significantly worse scores in four categories and 13 items compared with the lAD1 patients. Fewer differences in scores were found between eAD2 patients and the lAD3 patients than between the eAD1 patients and the lAD1 patients. Increasing severity of disease and rapid deterioration of patients with eAD, particularly during the first 3 years following disease onset, was recognized. The pattern of abnormalities on GBSS-JR showed no difference between the two broad groups (early versus late onset). The categorization of patients with Alzheimer's disease as early and late onset is relevant to clinical management.


1993 ◽  
Vol 10 (6) ◽  
pp. 489-494 ◽  
Author(s):  
Cheryl Faucett ◽  
W. James Gauderman ◽  
Duncan Thomas ◽  
Al Ziogas ◽  
Eugene Sobel

Neurogenetics ◽  
2007 ◽  
Vol 9 (1) ◽  
pp. 51-60 ◽  
Author(s):  
Joseph H. Lee ◽  
Sandra Barral ◽  
Rong Cheng ◽  
Inara Chacon ◽  
Vincent Santana ◽  
...  

2007 ◽  
Vol 16 (22) ◽  
pp. 2703-2712 ◽  
Author(s):  
Marian L. Hamshere ◽  
Peter A. Holmans ◽  
Dimitrios Avramopoulos ◽  
Susan S. Bassett ◽  
Deborah Blacker ◽  
...  

1996 ◽  
Vol 9 (1) ◽  
pp. 22-25 ◽  
Author(s):  
Joan M. Swearer ◽  
Brian F. O'Donnell ◽  
Susan M. Ingram ◽  
David A. Drachman

The clinical course of early-onset, dominantly inherited, familial Alzheimer's disease (FAD) was contrasted with late-onset, sporadic Alzheimer's disease (AD). Eight FAD and 23 sporadic AD patients were followed over a mean of 63 months from estimated disease onset. The two groups did not differ notably in duration of symptoms from onset, global disease severity, or degree of cognitive deficits on initial evaluation. The Kaplan-Meier lifetable method was used to assess time from estimated disease onset to dependence in self-care, institutionalization, and death. A greater percentage of FAD patients became dependent in self-care and died earlier than did sporadic AD patients. The lifetable results suggest that FAD may have a more rapid course than does late-onset sporadic AD.


2003 ◽  
Author(s):  
J. M. Silverman ◽  
C. J. Smith ◽  
D. B. Marin ◽  
R. C. Mohs ◽  
C. B. Propper

Author(s):  
Roja Rahimi ◽  
Shekoufeh Nikfar ◽  
Masoud Sadeghi ◽  
Mohammad Abdollahi ◽  
Reza Heidary Moghaddam ◽  
...  

Background: It has been found that there is a link between hypertension and elevated risk of Alzheimer’s disease (AD). Herein, a meta-analysis based on randomized clinical trials (RCTs) was used to assess the effect of antihypertensive drugs on cognition and behavioral symptoms of AD patients. Method: The three databases – PubMed/Medline, Scopus, and Cochrane Library- were searched up to March 2020. The quality of the studies included in the meta-analysis was evaluated by the Jadad score. Clinical Global Impression of Change (CGIC) included in two studies, Mini-Mental State Examination (MMSE) included in three studies, and Neuropsychiatric Inventory (NPI) in three studies were the main outcomes in this systematic review. Results: Out of 1506 studies retrieved in the databases, 5 RCTs included and analyzed in the meta-analysis. The pooled mean differences of CGIC, MMSE, and NPI in patients with AD receiving antihypertensive drugs compared to placebo was -1.76 with (95% CI = -2.66 to -0.86; P=0.0001), 0.74 (95% CI = 0.20 to 1.28; P= 0.007), and -9.49 (95% CI = -19.76 to 0.79; P = 0.07), respectively. Conclusion: The findings of the present meta-analysis show that antihypertensive drugs may improve cognition and behavioral symptoms of patients with AD. However, more well-designed RCTs with similar drugs are needed to achieve more conclusive results.


Sign in / Sign up

Export Citation Format

Share Document